DNLI

Denali Therapeutics (DNLI)

About Denali Therapeutics (DNLI)

Denali Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates for neurodegenerative diseases. Its product pipeline includes LRRK2, RIPK1, TREM2, and Tau. The company was founded by Ryan J. Watts, Marc Tessier-Lavigne, and Alexander Schuth on October 14, 2013 and is headquartered in San Francisco, CA.

Details

Daily high

$28.97

Daily low

$28.42

Price at open

$28.51

52 Week High

$32.13

52 Week Low

$14.56

Market cap

4.0B

Dividend yield

0.00%

Volume

108,131

Avg. volume

1.0M

P/E ratio

-9.89

Denali Therapeutics News